文献速递流行病学与生物统计真实世界研究与卫生经济医学教育与科研方法

大学医学中心临床试验透明度的机构仪表盘:一项案例研究

Institutional dashboards on clinical trial transparency for University Medical Centers: A case study.
PubMed 文献 · PLoS Med · 2023-03-21

本研究开发并应用半自动化方法,评估2009至2017年由35家德国大学医学中心主导的2895项干预性试验在注册、结果报告和开放获取方面的透明度实践,并构建交互式仪表盘展示各中心表现。研究发现前瞻性注册率上升,但摘要报告注册号、注册库链接发表物及按时结果报告的比例仍有限。

要点

  • 评估2895项德国大学医学中心干预性试验,覆盖前瞻性注册、结果报告和开放获取。
  • ClinicalTrials.gov注册试验前瞻性注册从33%升至75%,DRKS从0%升至79%。
  • 仅41%的试验在完成后2年内以论文或摘要结果形式按时报告。

核心结论

  • 本研究表明,以可重复且公开可访问的方式评估并告知各大学医学中心临床试验透明度表现是可行的。
  • 仪表盘可帮助机构评估其相对于 mandates 或机构政策的表现,并可能为增加透明实践采纳的干预提供信息,以及评估这些干预的影响。

研究设计与样本

  • 开发并应用半自动化方法,评估一组干预性试验及其相关结果发表物对既定透明度实践的依从性。
  • 试验需注册于ClinicalTrials.gov或德国临床试验注册库(DRKS),由德国大学医学中心主导,并于2009至2017年间报告完成。
  • 研究纳入并评估了由35家德国大学医学中心主导的2895项干预性试验。

主要发现

  • 在ClinicalTrials.gov注册的试验中,前瞻性注册从33%(n=58/178)增至75%(n=144/193);在DRKS注册的试验中从0%(n=0/44)增至79%(n=19/24)。
  • 在有结果发表物的试验中,38%(n=714/1895)在发表物摘要中报告了试验注册号。
  • 58%(n=861/1493)的ClinicalTrials.gov注册试验和23%(n=111/474)的DRKS注册试验在注册库中链接了发表物。
  • 8%(n=191/2253)的ClinicalTrials.gov到期试验和3%(n=20/642)的DRKS到期试验在注册库中有摘要结果。
  • 跨试验完成年份,按时结果报告(完成后2年内以稿件发表或摘要结果形式)为41%(n=1198/2892);开放获取试验发表物比例从42%(n=16/38)稳步增至74%(n=72/97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究的局限性在于,仪表盘中用于评估透明度实践的部分方法依赖于注册库数据准确且最新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: University Medical Centers (UMCs) must do their part for clinical trial transparency by fostering practices such as prospective registration, timely results reporting, and open access. However, research institutions are often unaware of their performance on these practices. Baseline assessments of these practices would highlight where there is room for change and empower UMCs to support improvement. We performed a status quo analysis of established clinical trial registration and reporting practices at German UMCs and developed a dashboard to communicate these baseline assessments with UMC leadership and the wider research community. METHODS AND FINDINGS: We developed and applied a semiautomated approach to assess adherence to established transparency practices in a cohort of interventional trials and associated results publications. Trials were registered in ClinicalTrials.gov or the German Clinical Trials Register (DRKS), led by a German UMC, and reported as complete between 2009 and 2017. To assess adherence to transparency practices, we identified results publications associated to trials and applied automated methods at the level of registry data (e.g., prospective registration) and publications (e.g., open access). We also obtained summary results reporting rates of due trials registered in the EU Clinical Trials Register (EUCTR) and conducted at German UMCs from the EU Trials Tracker. We developed an interactive dashboard to display these results across all UMCs and at the level of single UMCs. Our study included and assessed 2,895 interventional trials led by 35 German UMCs. Across all UMCs, prospective registration increased from 33% (n = 58/178) to 75% (n = 144/193) for trials registered in ClinicalTrials.gov and from 0% (n = 0/44) to 79% (n = 19/24) for trials registered in DRKS over the period considered. Of trials with a results publication, 38% (n = 714/1,895) reported the trial registration number in the publication abstract. In turn, 58% (n = 861/1,493) of trials registered in ClinicalTrials.gov and 23% (n = 111/474) of trials registered in DRKS linked the publication in the registration. In contrast to recent increases in summary results reporting of drug trials in the EUCTR, 8% (n = 191/2,253) and 3% (n = 20/642) of due trials registered in ClinicalTrials.gov and DRKS, respectively, had summary results in the registry. Across trial completion years, timely results reporting (within 2 years of trial completion) as a manuscript publication or as summary results was 41% (n = 1,198/2,892). The proportion of openly accessible trial publications steadily increased from 42% (n = 16/38) to 74% (n = 72/97) over the period considered. A limitation of this study is that some of the methods used to assess the transparency practices in this dashboard rely on registry data being accurate and up-to-date. CONCLUSIONS: In this study, we observed that it is feasible to assess and inform individual UMCs on their performance on clinical trial transparency in a reproducible and publicly accessible way. Beyond helping institutions assess how they perform in relation to mandates or their institutional policy, the dashboard may inform interventions to increase the uptake of clinical transparency practices and serve to evaluate the impact of these interventions.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Franzen DL, Carlisle BG, Salholz-Hillel M, et al. Institutional dashboards on clinical trial transparency for University Medical Centers: A case study. PLoS Med. 2023. PMID: 36943836. doi:10.1371/journal.pmed.1004175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。